Breast Cancer in 2025 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments in breast cancer
Faculty Chair
Joyce O’Shaughnessy, MD
Baylor Sammons Cancer Institute, Dallas, TX, USA
Faculty Members
Mark Pegram, MD
Stanford University School of Medicine, Stanford, CA, USA
Hope Rugo, MD, FASCO
City of Hope, Duarte, CA, USA
Kelly McCann, MD, PhD
UCLA Medicine, Los Angeles, CA, USA
William Gradishar, MD
Northwestern University, Chicago, IL, USA
Adam Brufsky, MD, PhD
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Peter Kaufman, MD
University of Vermont, Burlington, VT, USA
Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute, Boston, MA, USA
Jason Mouabbi, MD
MD Anderson Cancer Center, Houston, TX, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
The meeting report will be based on the following topics
- Current and Emerging Biomarkers and Testing Methodologies in Breast Cancer
- Evolving Standards for Early-Stage HER2+ Breast Cancer
- Optimizing the Management of HER2+ Advanced/Metastatic Breast Cancer With Current and Emerging Agents (not including HER2-low)
- HER2-Low Breast Cancer – Expanding the Spectrum of Targetability
- New Targets in HR+, HER2– Breast Cancer
- Evolving Paradigms in HR+, HER2– Metastatic Breast Cancer
- Current and Future Prospects for High-Risk, Early-Stage, Triple-Negative Breast Cancer (not including HER2-low)
- Current and Investigational Approaches in Metastatic Triple-Negative Breast Cancer (not including HER2-low)
- Expanding Options for High-Risk HR+, HER2– Early Breast Cancer
